Duration of acute kidney injury and mortality in critically ill patients: a retrospective observational study by Seung Seok Han et al.
Han et al. BMC Nephrology 2013, 14:133
http://www.biomedcentral.com/1471-2369/14/133RESEARCH ARTICLE Open AccessDuration of acute kidney injury and mortality in
critically ill patients: a retrospective observational
study
Seung Seok Han1†, Sejoong Kim1,2†, Shin Young Ahn1,2, Jeonghwan Lee3, Dong Ki Kim1, Ho Jun Chin1,2,
Dong-Wan Chae1,2 and Ki Young Na1,2*Abstract
Background: The addition of relevant parameters to acute kidney injury (AKI) criteria might allow better prediction of
patient mortality than AKI criteria alone. Here, we evaluated whether inclusion of AKI duration could address this issue.
Methods: AKI was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines in 2,143
critically ill patients, within 15 days of patient admission. AKI cases were categorized according to tertiles of AKI
duration: 1st tertile, 1–2 days; 2nd tertile, 3–5 days; and 3rd tertile, ≥6 days. The hazard ratios (HRs) for overall survival
rates in three groups were calculated after adjustment for multiple covariates compared with ICU patients without AKI
as the reference group. The predictive ability for mortality was assessed by calculating the area under the curve (AUC)
of the receiver operating characteristic curve.
Results: AKI increased the HRs for overall mortality, and the mortality rate increased with AKI duration: the adjusted
HRs were 1.99 (1st tertile), 2.67 (2nd tertile), and 2.85 (3rd tertile) compared with the non-AKI group (all Ps < 0.001). The
AUC of the ROC curve for overall mortality based on the AKI duration groups (0.716) was higher than the AUC of AKI
staging using the KDIGO guidelines (0.696) (P = 0.001). When considering KDIGO stage and AKI duration together, the
AUC (0.717) was also significantly higher than that using the KDIGO stage alone (P < 0.001).
Conclusions: AKI duration is an additional parameter for the prediction of mortality in critically ill patients. The
inclusion of AKI duration could be considered as a refinement of the AKI criteria.
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Acute kidney injury (AKI) is an important field of study
in nephrology because AKI leads to long-term kidney
sequelae, such as chronic kidney disease (CKD) and end-
stage kidney disease [1,2]. Furthermore, AKI affects the fate
of other organs and overall mortality [3,4]. Although ther-
apy for AKI has improved in recent years, AKI is still highly
prevalent, especially in critically ill patients in the intensive
care unit (ICU) [5]. AKI in the ICU has high mortality
rates, reaching 80% [6]; these rates have remained largely* Correspondence: kyna@snubh.org
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reproduction in any medium, provided the orunchanged despite improvements in therapies [7]. For
these reasons, the diagnosis of AKI and its classification
according to severity are of major importance for clinicians
in managing AKI patients.
Efforts have been made to define and stage AKI cases
for use in clinical practice and research. Various criteria
for AKI were used in early studies; the first evidence-
based consensus, the RIFLE classification, was established
by the Acute Dialysis Quality Initiative (ADQI) group [8].
The RIFLE classification defines grades of AKI according
to changes in serum creatinine, glomerular filtration rate
(GFR), and/or urine output. This RIFLE classification was
further refined by the Acute Kidney Injury Network
(AKIN) group [9]. The most noticeable change in the AKI
criteria defined by AKIN was the inclusion of a smaller
change in serum creatinine (≥ 0.3 mg/dL), which may. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Disease: Improving Global Outcomes (KDIGO) proposed
a new set of guidelines for the definition and classification
of AKI based on the previous two classifications [10].
Whereas the urine output criterion (UOCr) did not change,
some changes in the serum creatinine criterion (CrCr) were
made for further clarity and simplicity.
Several epidemiological studies have supported the
validity of AKI criteria in predicting mortality. However,
identifying only changes in serum creatinine and urine
output is not sufficient to improve the reliability of the
criteria, thus other factors should be considered. One of
the most readily confirmable factors in clinical practice
is the duration of AKI. Three previous studies evaluated the
association between AKI duration and mortality [11-13],
but these results were limited because critically ill patients
admitted to the ICU, where the observed negative impact
of AKI is the greatest, were not included and because
UOCr was not considered. Here, we assessed AKI duration
using CrCr and UOCr from the KDIGO guidelines in a
large cohort of ICU patients. Using these data, we com-
pared the ability to predict mortality from AKI duration,
from the conventional AKI stages, and from AKI duration
and stage together to evaluate whether the inclusion of AKI
duration could allow better predictions of patient mortality
than the conventional AKI criteria alone.
Methods
Patients and data collection
The institutional review board at the Seoul National
University Bundang Hospital approved the study
(no. B-1112-142-103). A total of 2,823 patients were
admitted from June 2004 through June 2010 to the ICU
at the Seoul National University Bundang Hospital,
Gyeonggi-do, Korea. The patients were followed up until
December 31, 2010. We excluded patients younger than
18 years old (n = 49) and patients previously diagnosed
with end-stage renal disease on dialysis (n = 94). Two
patients who remained in hospital at the end of the study
were also excluded. Among the study subjects, 9 patients
were excluded based on the unavailability of serum creatin-
ine or urine output data. If the patients were admitted more
than once to the ICU without AKI, only the first admission
was counted as the single case. Consequently, 2,143
patients were reviewed retrospectively using electronic
medical records. A standardized data form approved by the
institutional review board was used to collect the data.
Clinical parameters, such as age, sex, weight (kg), systolic/
diastolic blood pressure, primary diagnosis, underlying
CKD, history of malignancy, the need for mechanical
ventilation, and the use of vasoactive drugs were recorded.
The primary diagnosis was categorized as cardiovascular
disease, sepsis, surgical admission, and others. The Acute
Physiology and Chronic Health Evaluation (APACHE) ІІscore was used to assess illness severity [14]. Changes in
serum creatinine and urine output after ICU admission
were measured, and the urine output data were recorded
hourly. Additionally, we gathered laboratory blood data
such as white blood cell count, hemoglobin, platelet count,
blood urea nitrogen, cholesterol, protein, bilirubin, aspar-
tate aminotransferase, alanine aminotransferase, and alka-
line phosphatase; there was only about 1% of data missing.
Definition and classification of acute kidney injury
Definition and staging of AKI were complied with the
KDIGO guidelines, which is comprised of CrCr and UOCr
(Table 1). Patients were classified as having no AKI or AKI
according to the worst stage achieved after admission to
the ICU. In the AKI group, the duration of AKI was defined
by the number of days that AKI was present from 1 day to
the end of AKI (a maximum of 15 days). The end of AKI
was determined when it did not conform to the criteria of
AKI. For analyses, patients with AKI were divided into
three groups according to the tertiles of AKI duration; 1 to
2 days (1st tertile), 3 to 5 days (2nd tertile), and at least 6 days
(3rd tertile). Because renal replacement therapy (RRT) can
confound AKI duration [15], we categorized patients who
underwent RRT into another study group independent of
AKI duration. Accordingly, all of the subjects were catego-
rized into the following five groups: the non-AKI group,
the 1st tertile group, the 2nd tertile group, the 3rd tertile
group, and the RRT group. Recovery from AKI was also
examined, and was defined as a return to baseline values of
serum creatinine and normal range of urine output within
3 months after AKI event. In-hospital and overall mortal-
ities were selected as mortality outcome; all-cause mortality
was considered to be the primary outcome. The mortality
data were obtained from hospital records and from the
national database of Statistics Korea.
Statistical analysis
All of the analyses and calculations were performed using
SPSS (SPSS version 16.0, IBM, Armonk, NY, USA) and
MedCalc software (MedCalc version 11.5.1, Mariakerke,
Belgium). The data are presented as means ± standard devi-
ation (SD) for continuous variables and as proportions for
categorical variables. Variables with a non-normal distribu-
tion are expressed as median (interquartile range (IQR)).
The in-hospital survival rates and the overall survival rates
which were recorded after the patients had been discharged
were calculated using the Kaplan-Meier method. The sur-
vival comparison among the groups based on KDIGO stage
or AKI duration was performed using the log-rank test.
The hazard ratios (HRs) and 95% confidence intervals (CIs)
for mortality rates were calculated using the Cox propor-
tional hazard model after adjustment for potential con-
founders, including age, sex, APACHE ІІ score, primary
diagnosis, underlying CKD, history of malignancy, the need
Table 1 Definition and staging for acute kidney injury
Serum creatinine criterion Urine output criterion
Stage 1 ≥ 0.3 mg/dl increase within 48
hours or 1.5–1.9 times baseline
< 0.5 ml/kg/h for
6–12 hours
Stage 2 2.0–2.9 times baseline < 0.5 ml/kg/h
for≥ 12 hours
Stage 3 ≥ 3.0 times baseline or increase in
serum creatinine to≥ 4.0 mg/dl, or
initiation of renl replacement therapy
< 0.3 ml/kg/h for
≥ 24 hours or anuria
for≥ 12 hours
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AKI stage. ICU patients without AKI were used as the
reference group. For additional analyses, lengths of hospital
stay were compared among the AKI duration groups using
the Mann–Whitney U test or Kruskal-Wallis test according
to the number of groups. The relationship between
AKI duration and AKI recovery was evaluated using a
Chi-square test. A goodness of fit test was used to
evaluate the applicability of the model. The discriminative
ability of the criteria to correctly predict mortality was
assessed by calculating the area under the curve (AUC) of
the receiver operating characteristic (ROC) curve. A com-
parison of the ROC curves was performed using a method
described by DeLong and colleagues [16]. A P value of less
than 0.05 was considered to be significant.
Results
Baseline characteristics
Table 2 shows the baseline characteristics of the study sub-
jects. The mean age was 68 years. All of the subjects were
of Asian descent. Most of the patients were admitted to the
ICU because of medical problems (n = 2097) rather than
surgical problems (n = 46). More specifically, 649 patients
(30.3%) were admitted to the ICU because of cardiovascular
disease. Sepsis was the cause of admission for 197 patients
(4.5%). The mean APACHE ІІ score was 18.1. The median
length of stay in hospital was 21 days (IQR, 11 to 43 days).
The study subjects were followed for a median duration of
137 days (IQR, 21 to 466 days).
Acute kidney injury and its duration
Of the total number of subjects, 1655 (77.2%) were de-
termined to have AKI within 15 days of ICU admission.
Each AKI case was diagnosed by CrCr alone (66.4%), UOCr
alone (2.9%), or both (30.7%). Among the patients with
AKI, the proportion in each AKI stage was as follows: stage
1, 46.5%; stage 2, 27.2%; and stage 3, 26.3%. A total of 169
patients received RRT within 15 days of ICU admission.
Throughout the following period, 1,166 (54.4%) of all ICU
patients died, and the mortality rate was 169.1 deaths per
100,000 patient-days. The overall mortality rate of the
patients with AKI was higher than that of the non-AKI
patients (215.3 vs. 64.4 deaths per 100,000 patient-days,
P < 0.001). Figure 1 shows the overall survival curves whenthe patients were divided into four groups according to the
KDIGO guidelines (P < 0.001 by the log-rank test). The
HRs (95% CIs) for overall mortality according to AKI stage
vs. no AKI were as follows: stage 1, 2.08 (1.71–2.52); stage
2, 3.00 (2.45–3.68); and stage 3, 5.14 (4.21–6.28).
The mean duration of AKI among all AKI patients
was 4.5 days (median, 4 days; IQR, 2 to 7 days). The
mean duration of AKI when the patients who received
RRT were not considered in the analysis was 4.1 days
(median, 3 days; IQR, 2 to 6 days). A 1-day increase in AKI
duration led to an 11.7% increase in the overall mortality
rate (P < 0.001). After excluding the patients who received
RRT, a 1-day increase in AKI duration was associated with
a 13.9% increase in the overall mortality rate (P < 0.001).
The AKI patients who did not receive RRT were divided
into three groups according to the tertiles of AKI duration:
1st tertile (n = 552), 1–2 days; 2nd tertile (n = 497), 3–5 days;
and 3rd tertile (n = 437), ≥ 6 days. 92.6% (1st tertile), 98.8%
(2nd tertile), and 100% (3rd tertile) of AKI cases could be
determined by CrCr alone, whereas 17.0% (1st tertile),
30.2% (2nd tertile), and 38.2% (3rd tertile) of AKI cases could
be determined by UOCr alone. The RRT group was defined
using CrCr alone (100%), but the RRT group also had AKI
cases determined by UOCr alone (85.8%). Figure 2 shows
the overall survival curves according to the tertiles of AKI
duration; the overall survival rates among the five groups
were significantly different (P < 0.001 by the log-rank test).
The HRs for mortality are shown in Table 3. The mortality
rates of the AKI groups were higher than those of the non-
AKI group (all Ps < 0.001). After adjusting for multiple
confounding factors including age, sex, APACHE ІІ score,
primary diagnosis, underlying CKD, history of malignancy,
the need for mechanical ventilation, the use of vasoactive
drugs, and AKI stage, the HRs for mortality remained sig-
nificant (all Ps < 0.001). Figure 3 shows the overall survival
curves for the AKI duration groups for each AKI stage
(according to the KDIGO guidelines). The overall survival
rates among the AKI groups for each AKI stage were
significantly different (all P < 0.05 by the log-rank test). The
lengths of hospital stay (Table 2) were different among the
AKI duration groups (P < 0.001); the duration of stay for
the non-AKI group was shorter than those of the 1st, 2nd
and 3rd tertile groups (P = 0.004 for 1st tertile and Ps < 0.001
for 2nd and 3rd tertiles), but was longer than that of the
RRT group (P = 0.024). The proportions of recovery from
AKI were significantly different among the AKI groups: 1st
tertile group, 90.4%; 2nd tertile group, 74.4%; 3rd tertile
group, 59.0%; RRT group, 21.3% (P < 0.001).
Predicting mortality based on the duration of acute
kidney injury
The AUC (95% CI) of the ROC curve for overall mortality
was 0.696 (0.676–0.715) when AKI was staged according
to the KDIGO guidelines, and 0.716 (0.697–0.735) for
Table 2 Baseline characteristics and laboratory findings of the patients at the time of admission to the intensive care unit
No AKI (n = 488) 1st tertile (n = 552) 2nd tertile (n = 497) 3rd tertile (n = 437) RRT (n = 169)
Age (years) 65.0 ± 16.11 66.8 ± 16.49 69.5 ± 15.40 69.7 ± 15.34 66.2 ± 14.30
Male sex (%) 52.5 63.9 59.6 59.3 68.0
Body weight (kg) 58.1 ± 11.61 59.0 ± 13.19 57.1 ± 11.94 57.8 ± 13.45 62.0 ± 11.09
Primary diagnosis
Cardiovascular disease 39.1 27.4 30.4 27.7 20.1
Sepsis 1.6 3.3 4.8 5.0 14.8
Surgical emergency 3.7 2.5 1.2 1.6 0.6
Others 55.5 66.7 63.6 65.7 64.5
Underlying CKD 5.5 6.9 9.3 9.8 22.5
History of malignancy 16.2 14.7 17.1 19.9 24.3
Need for MV 51.2 62.9 76.7 81.2 78.1
Use of vasoactive drugs 24.2 44.9 59.8 65.7 75.1
SBP (mmHg) 133.1 ± 31.37 132.3 ± 33.58 128.1 ± 35.15 128.4 ± 36.02 118.4 ± 32.54
DBP (mmHg) 71.1 ± 23.61 70.1 ± 26.18 64.8 ± 26.81 63.6 ± 28.42 56.2 ± 25.59
White blood cells (1000/mm3)* 9.5 (7.09–12.69) 10.7 (7.40–14.42) 10.9 (7.53 – 15.37) 10.4 (7.45–14.57) 10.1 (7.00–15.67)
Hemoglobin (g/dL) 12.8 ± 2.32 12.7 ± 2.63 12.0 ± 2.58 11.7 ± 2.74 10.8 ± 2.90
Platelet (1000/μL)* 237 (185–294) 217 (163–289) 214 (156–294) 217 (144–292) 177 (88–261)
Blood urea nitrogen (mg/dL)* 15 (11–20) 18 (13–26) 22 (14–34) 22 (14–39) 34 (20–66)
Creatinine (mg/dL)* 0.9 (0.7–1.1) 1.1 (0.8–1.3) 1.2 (0.9–1.7) 1.2 (0.8–1.9) 2.0 (1.1–3.9)
Cholesterol (mg/dL) 170.0 ± 49.48 161.5 ± 56.57 152.4 ± 52.38 153.2 ± 59.00 138.6 ± 50.88
Protein (g/dL) 6.6 ± 0.99 6.5 ± 1.03 6.4 ± 1.04 6.2 ± 1.05 6.1 ± 1.07
Bilirubin (mg/dL)* 0.7 (0.5–1.0) 0.8 (0.6–1.1) 0.8 (0.6–1.2) 0.7 (0.5–1.1) 0.9 (0.5–1.5)
GOT (mg/dL)* 26 (19–39) 31 (20–51) 33 (22–67) 31 (21–58) 36 (22–98)
GPT (mg/dL)* 22 (14–33) 22 (12–41) 22 (14–43) 23 (14–48) 28 (15–65)
Alkaline phosphatase (mg/dL)* 76 (63–99) 83 (63–106) 82 (64–112) 85 (65–118) 84 (66–122)
APACHE ІІ score 13.4 ± 6.51 16.7 ± 7.33 20.7 ± 7.80 20.3 ± 7.86 22.1 ± 8.51
LOS in hospital (days)* 16 (9–35) 21 (11–38) 22 (11–51) 29 (14–54) 13 (7–28)
*Data are expressed as the median (interquartile range).
Duration of acute kidney injury: 1st tertile, 1–2 days; 2nd tertile, 3–5 days; 3rd tertile, ≥ 6 days.
AKI Acute kidney injury, RRT Renal replacement therapy, CKD Chronic kidney disease, MV Mechanical ventilation, SBP Systolic blood pressure, DBP Diastolic blood
pressure, APACHE Acute Physiology and Chronic Health Evaluation, LOS Length of stay.
Han et al. BMC Nephrology 2013, 14:133 Page 4 of 7
http://www.biomedcentral.com/1471-2369/14/133the AKI duration groups (P = 0.001). When AKI duration
was considered as a continuous variable (0 to 15 days),
the AUC was 0.718 (0.698–0.737); the AUC was 0.711
(0.690–0.731) in the patients who did not receive RRT.
The AUC for overall mortality in patients who did not
receive RRT was analyzed according to duration as de-
termined by each criterion with the following results:
AKI duration using CrCr, 0.670 (0.648–0.690), and AKI
duration using UOCr, 0.596 (0.574–0.618). When con-
sidering AKI staging according to the KDIGO guidelines
and AKI duration together, the AUC for overall mortal-
ity (0.717 (0.697–0.736)) was significantly higher than
the AUC calculated from the AKI staging (P < 0.001).
The AUCs for in-hospital mortality were also higher
when using AKI staging and AKI duration together(0.751 (0.732–0.769)) than the AUCs calculated using
only AKI staging (0.731 (0.712–0.750)) (P < 0.001).
Discussion
AKI worsens the survival of patients with a variety of
presenting conditions, especially critically ill patients.
Several factors in addition to those currently measured
may be involved in the inverse association of AKI with
survival. This study shows that AKI duration is an add-
itional predictive parameter for mortality during and
after ICU admission. In addition to revealing a strong
correlation between AKI duration and mortality, the
present data has several strengths. First, we adopted the
KDIGO guidelines for AKI, which are the most recently
revised guidelines, offering clarity and simplicity in clinical
Figure 1 Overall survival curves of critically ill patients according
to the KDIGO (Kidney Disease: Improving Global Outcomes)
guidelines for acute kidney injury. The overall survival rates of the
four groups were significantly different (P < 0.001 by the log-rank test).
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hourly collection of urine output is essential in staging
and defining AKI, but can be difficult and thus has rarely
been considered in most previous studies. Therefore, our
study results may be a good reference for future studies
using the KDIGO guidelines. The second strength of this
study is that patients admitted to the ICU were includedFigure 2 Overall survival curves of critically ill patients according
to the duration of acute kidney injury. The overall survival rates of the
five groups were significantly different (P< 0.001 by the log-rank test).
Duration of acute kidney injury: 1st tertile, 1–2 days; 2nd tertile,
3–5 days; 3rd tertile, ≥ 6 days. RRT, patients who underwent renal
replacement therapy.in our analysis. Two previous studies on AKI duration
have used a cohort of patients who underwent cardiac
or noncardiac surgery [12,13]. However, those studies
did not cover a heterogeneous population of critically ill
patients, who are most vulnerable to AKI.
The detection and classification of AKI is important
for determining patient prognosis. The RIFLE and AKIN
criteria used to define AKI have been shown to be good
predictors of patient prognosis [17,18]. The KDIGO
guidelines, which represent a combination of RIFLE and
AKIN criteria, may also allow the prediction of morbidity
and mortality, although few studies using this guideline
have been conducted so far. However, the AKI criteria
have not yet been fully optimized: some cases of AKI can
remain undiagnosed [19,20]; a non-gradual increase in
mortality with increasing AKI stage has been shown in
some studies [19-22]. These problems can be explained by
shortcoming of serum creatinine as an early AKI marker
[23], limitation in the use of UOCr [24], and the failure to
identify other factors such as the cause of AKI [25]. We
were interested primarily in the latter point; among several
other predictive factors, we focused on the effect of AKI
duration, because this can be easily measured without
further extensive tests.
In this study, patients with a long duration of AKI had
higher mortality rates and longer hospital stays than
patients with a short duration of AKI. The strong cor-
relation between AKI duration and poor outcome can
be explained as follows: the more severe and treatment-
resistant an AKI case is (e.g., non-recovery case), the
longer the duration of AKI become. Three previous studies
investigated this issue by dividing patients into groups:
transient azotemia (≤ 3 days) and acute tubular necrosis
(≥ 4 days or patients with RRT) [11]; short (≤ 2 days),
medium (3–6 days), and long (≥ 7 days or patients with
RRT) [12,13]. However, we set the patients with RRT
apart because patients who received RRT may have
cases of AKI that are much more severe than those of
other patients and because RRT shortens the duration
of AKI compared with other medical treatments [15].
Based on the results thus far, it can be concluded that the
effort to recover from AKI is an important consideration,
particularly for long-term AKI cases. AKI is not merely a
disease of the kidneys, as it can also affect the functioning
or failure of other organs [3]. Therefore, early detection
and early treatment of AKI are essential to reduce the
negative impact of AKI. However, the present study does
not underestimate the importance of transient AKI,
because short-duration AKI was also found to increase
mortality significantly compared to no AKI, and a 1-day
increase in AKI duration was associated with a 13.9%
increase in overall mortality.
The ability to predict mortality was compared be-
tween AKI duration groups and conventional AKI stages
Table 3 Hazard ratios (95% confidence intervals) for mortality according to the duration of acute kidney injury
Unadjusted HR Adjusted HR*
Duration groups In-hospital mortality Overall mortality In-hospital mortality Overall mortality
No AKI (n = 488) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
1st tertile (n = 552) 2.07 (1.41–3.02) 1.77 (1.43–2.18) 3.22 (2.03–5.13) 1.99 (1.48–2.67)
2nd tertile (n = 497) 3.83 (2.69–5.46) 2.97 (2.43–3.63) 4.29 (2.83–6.51) 2.67 (2.04–3.50)
3rd tertile (n = 437) 4.43 (3.12–6.30) 3.85 (3.15–4.70) 3.64 (2.48–5.35) 2.85 (2.24–3.64)
RRT (n = 169) 8.97 (6.18–13.02) 5.73 (4.51–7.27) 5.57 (3.76–8.25) 3.83 (2.96–4.95)
HR, Hazard ratio; AKI, Acute kidney injury; RRT, Renal replacement therapy.
*Adjusted for age, sex, APACHE ІІ score, primary diagnosis, underlying CKD, history of malignancy, the need for mechanical ventilation, the use of vasoactive
drugs, and AKI stages.
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curves. The AUCs of the ROCs indicated that AKI
duration had greater ability to predict mortality than the
conventional AKI stages. Furthermore, when considering
AKI duration and AKI staging together, the ability to
predict mortality was superior to the results based on the
analysis of AKI staging alone. These results suggest that the
AKI duration could be considered as an extra parameter to
increase the sensitivity of the KDIGO criteria. Additionally,Figure 3 Overall survival curves according to the duration of acute kidne
Duration of acute kidney injury: 1st tertile, 1–2 days; 2nd tertile, 3–5 days; 3rd tertiif AKI staging is not carried out, then AKI duration can be
used as a replacement to predict mortality.
Although our results are informative, this study has
some limitations. First, the ICU design of the study
limits the applicability of our conclusions to other set-
tings despite the abundance and detail of the dataset; the
proportion of patients with sepsis as a cause of admission
was relatively low. Second, we did not control for the use
or indication of treatment for AKI because AKI durationy injury in each KDIGO stage: stage 1 (A), stage 2 (B), and stage 3 (C).
le, ≥ 6 days. RRT, patients who underwent renal replacement therapy.
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Further studies addressing these limitations will be ne-
cessary in the future.
Conclusions
In conclusion, AKI duration is a useful parameter for the
prediction of mortality in critically ill patients. Comparable
predictions of mortality can be made from AKI duration
alone. Furthermore, the prediction of mortality can be
improved when considering AKI duration in addition to
the current AKI criteria. Although the current criteria
for detecting and staging AKI are useful in clinical practice
and research, the results of the current study should be
considered in future refinements of the AKI criteria.
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